(1-benzyl-piperidin-4-yl)-(3-methoxy-phenyl)-amine | 202859-14-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (1-benzyl-piperidin-4-yl)-(3-methoxy-phenyl)-amine
• 英文别名: 1-Benzyl-4-(3-methoxyphenyl)aminopiperidine；N-(3-methoxyphenyl)-1-(phenylmethyl)-4-piperidinamine；1-benzyl-N-(3-methoxyphenyl)piperidin-4-amine
• CAS: 202859-14-1
• 化学式: C₁₉H₂₄N₂O
• 分子量: 296.412
• InChiKey: REXBHXOYMGXVAB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  24.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  草酰氯 、 (1-benzyl-piperidin-4-yl)-(3-methoxy-phenyl)-amine 在 三氯化铝 碳酸氢钠 作用下， 以 二氯甲烷 为溶剂， 以73%的产率得到1-(1-benzylpiperidin-4-yl)-6-methoxyindoline-2,3-dione
  参考文献：
  名称：

  Indoles

  摘要：

  一种由以下公式表示的1,4-取代的环胺衍生物或其药理学上可接受的盐： 其中A、B、C、D、T、Y和Z分别表示亚甲基或氮键合物；R1、R2、R3、R4和R5分别表示取代基；n表示0或1至3的整数；m表示0或1至6的整数；p表示1至3的整数。这些化合物具有5-羟色胺拮抗作用。因此，在临床上作为药物特别有用，用于治疗、改善和预防痉挛性瘫痪。它们还可用作中枢肌肉松弛剂，改善肌张力过高。

  公开号：

  US20020019531A1
• 作为产物：
  描述：

  N-苄基哌啶酮 、 间氨基苯甲醚 在 titanium(IV) isopropylate 、 sodium tetrahydroborate 作用下， 以 乙醇 为溶剂， 生成 (1-benzyl-piperidin-4-yl)-(3-methoxy-phenyl)-amine
  参考文献：
  名称：

  N,N-Diethyl-4-[(3-hydroxyphenyl)(piperidin-4-yl)amino] benzamide derivatives: The development of diaryl amino piperidines as potent δ opioid receptor agonists with in vivo anti-nociceptive activity in rodent models

  摘要：

  We have investigated a series of phenolic diaryl amino piperidine delta opioid receptor agonists, establishing the importance of the phenol functional group and substitution on the piperdine nitrogen for delta agonist activity and selectivity versus the mu and kappa opioid receptors. This study uncovered compounds with improved agonist potency and selectivity compared to the standard, non-peptidic delta agonist SNC-80. In vivo anti-nociceptive activity of analog 8e in two rodent models is discussed, demonstrating the potential of delta agonists to provide a novel mechanism for pain relief. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.09.072

文献信息

• Novel compounds
  申请人：——

  公开号：US20030036552A1

  公开（公告）日：2003-02-20

  Compounds of general formula (I), R 1 is selected from any one of phenyl, pyridinyl, thiophenyl, furanyl, imidazolyl, and triazolyl; where each R 1 phenyl ring and R 1 heteroaromatic ring may optionally and independently be further substituted by 1, 2 or 3 substituents selected from straight and branched C 1 -C 6 alkyl, NO 2 , CF 3 , C 1 -C 6 alkoxy, chloro, fluoro, bromo, and iodo. The substitutions on the phenyl ring and on the heteroaromatic ring may take place in any position on said ring systems; R a and R b is each and individually selected from any one of hydrogen, a straight and branched C 1 -C 6 alkyl, NO 2 , CF 3 , C 1 -C 6 alkoxy, chloro, fluoro, bromo, and iodo; are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts and pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.

  通式（I）的化合物，其中R1可选择自苯基、吡啶基、噻吩基、呋喃基、咪唑基和三唑基中的任意一种；其中每个R1苯环和R1杂环环可能可选地且独立地进一步被1、2或3个取代基所取代，所述取代基可选择自直链和支链的C1-C6烷基、NO2、CF3、C1-C6烷氧基、氯、氟、溴和碘。苯环和杂环上的取代作用可以发生在所述环系统的任何位置；Ra和Rb各自选择自氢、直链和支链的C1-C6烷基、 、 、C1-C6烷氧基、氯、氟、溴和碘；本申请中披露和索要了这些化合物及其药学上可接受的盐和包含这些新化合物的制药组合物，以及它们在治疗中的用途，特别是在疼痛管理中的用途。
• Quinoline derivatives
  申请人：Eisai Co., Ltd.

  公开号：US07071201B2

  公开（公告）日：2006-07-04

  A novel compound of the formula: wherein A, B, C, D, T, Y, and Z represent each methine or nitrogen; R1, R2, R3, R4, and R5 represent each a substituent; n represents 0 or an integer of 1 to 3; m represents 0 or an integer of 1 to 6; and p represents an integer of 1 to 3; and pharmacologically acceptable salts thereof. The compound has a serotonin antagonism and is clinically useful as medicament, in particular, for treating, ameliorating and preventing spastic paralysis or central muscle relaxants for ameliorating myotonia.

  一种新型化合物的公式：其中A、B、C、D、T、Y和Z分别代表亚甲基或氮；R1、R2、R3、R4和R5分别代表取代基；n代表0或1至3的整数；m代表0或1至6的整数；p代表1至3的整数；以及其药理学上可接受的盐。该化合物具有5-羟色胺拮抗作用，临床上可作为药物使用，特别是用于治疗、改善和预防痉挛性瘫痪或中枢肌肉松弛剂以改善肌强直症状。
• Certain quinoline derivatives
  申请人：Eisai Co., Ltd.

  公开号：US20020086999A1

  公开（公告）日：2002-07-04

  A novel 1,4-substituted cyclic amine derivative represented by the following formula: 1 wherein A, B, C, D, T, Y, and Z represent each methine or nitrogen; R 1 , R 2 , R 3 , R 4 , and R 5 represent each a substituent; n represents 0 or an integer of 1 to 3; m represents 0 or an integer of 1 to 6; and p represents an integer of 1 to 3; and pharmacologically acceptable salts thereof. The compound has a serotonin antagonism and is clinically useful as medicament, in particular, for treating, ameliorating and preventing spastic paralysis or central muscle relaxants for ameliorating myotonia.

  由下式表示的新型 1,4-取代环胺衍生物： 1 其中 A、B、C、D、T、Y 和 Z 分别代表甲烷或氮； R 1 , R 2 , R 3 , R 4 和 R 5 分别代表一个取代基；n 代表 0 或 1 至 3 的整数；m 代表 0 或 1 至 6 的整数；p 代表 1 至 3 的整数；及其药理上可接受的盐类。该化合物具有血清素拮抗作用，在临床上可用作药物，特别是用于治疗、改善和预防痉挛性瘫痪或用于改善肌张力的中枢性肌肉松弛剂。
• Process for the preparation diaryl-4-amino-piperidinyl compounds
  申请人：——

  公开号：US20040068112A1

  公开（公告）日：2004-04-08

  The present invention discloses a new and improved process for the preparation 1-substituted diaryl-4-amino-piperidinyl compounds by a one-pot double arylation followed by optional deprotection step(s).

  本发明公开了一种新的改进工艺，通过一锅双芳基化，然后任选进行脱保护步骤，制备 1-取代二芳基-4-氨基哌啶化合物。
• Pharmacological profile of a novel series of NK1 antagonists. In vitro and in vivo potency of benzimidazolone derivatives
  作者：G Rémond、B Portevin、J Bonnet、E Canet、D Regoli、G De Nanteuil

  DOI：10.1016/s0223-5234(97)82771-7

  日期：1997.11

  By low throughput examination of our chemical library, compound 7 was selected as a lead NK, antagonist with a K-i of 7.1 nM. Modifications of its structure led to the finding that the in vitro potency could be markedly enhanced by disubstituting the anilino phenyl ring as in compounds 13 or 22. Human binding data correlated rather well with results obtained with in vitro animal mice; compound 13 was the most active with ED50 of 0.001 and 0.3 mg/kg after iv and po administration respectively. Furthermore, antagonist 71 was found to be a potent inhibitor of SP-induced bronchoconstriction in guinea-pigs with an ED50 between 0.1 and 0.03 mg/kg iv. Furthermore, upon oral administration, 71 was observed to be active in a model of SP-induced bronchial hypersensitivity in mice, with an ID50 of around 3 mg/kg.